These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26430887)

  • 1. Risk Knowledge in Relapsing Multiple Sclerosis (RIKNO 1.0)--Development of an Outcome Instrument for Educational Interventions.
    Heesen C; Kasper J; Fischer K; Köpke S; Rahn A; Backhus I; Poettgen J; Vahter L; Drulovic J; Van Nunen A; Beckmann Y; Liethmann K; Giordano A; Fulcher G; Solari A;
    PLoS One; 2015; 10(10):e0138364. PubMed ID: 26430887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What should a person with relapsing-remitting multiple sclerosis know? - Focus group and survey data of a risk knowledge questionnaire (RIKNO 2.0).
    Heesen C; Pöttgen J; Rahn AC; Liethmann K; Kasper J; Vahter L; Drulovic J; Van Nunen A; Wilkie D; Beckmann Y; Paul F; Köpke S; Giordano A; Solari A;
    Mult Scler Relat Disord; 2017 Nov; 18():186-195. PubMed ID: 29141808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating Relapse Knowledge in People with Multiple Sclerosis: A Cross-Sectional Study on the Development and Validation of the Relapse Knowledge Questionnaire.
    Wenzel L; Haker M; Heesen C; Kasper J; Köpke S; Rahn AC
    Mult Scler Relat Disord; 2024 Mar; 83():105381. PubMed ID: 38308915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk knowledge of people with relapsing-remitting multiple sclerosis - Results of an international survey.
    Giordano A; Liethmann K; Köpke S; Poettgen J; Rahn AC; Drulovic J; Beckmann Y; Sastre-Garriga J; Galea I; Heerings M; Jongen PJ; Vettorazzi E; Solari A; Heesen C;
    PLoS One; 2018; 13(11):e0208004. PubMed ID: 30496233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluator-blinded trial evaluating nurse-led immunotherapy DEcision Coaching In persons with relapsing-remitting Multiple Sclerosis (DECIMS) and accompanying process evaluation: study protocol for a cluster randomised controlled trial.
    Rahn AC; Köpke S; Kasper J; Vettorazzi E; Mühlhauser I; Heesen C
    Trials; 2015 Mar; 16():106. PubMed ID: 25872529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
    Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
    JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial.
    Köpke S; Kern S; Ziemssen T; Berghoff M; Kleiter I; Marziniak M; Paul F; Vettorazzi E; Pöttgen J; Fischer K; Kasper J; Heesen C
    J Neurol Neurosurg Psychiatry; 2014 Apr; 85(4):411-8. PubMed ID: 24104856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency.
    Zamboni P; Galeotti R; Menegatti E; Malagoni AM; Gianesini S; Bartolomei I; Mascoli F; Salvi F
    J Vasc Surg; 2009 Dec; 50(6):1348-58.e1-3. PubMed ID: 19958985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the effect of an evidence-based patient online educational tool for people with multiple sclerosis called UMIMS-understanding magnetic resonance imaging in multiple sclerosis: study protocol for a double-blind, randomized controlled trial.
    Schiffmann I; Freund M; Vettorazzi E; Stellmann JP; Heyer-Borchelt S; D'Hooghe M; Häußler V; Rahn AC; Heesen C
    Trials; 2020 Dec; 21(1):1008. PubMed ID: 33298133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
    Burt RK; Loh Y; Cohen B; Stefoski D; Balabanov R; Katsamakis G; Oyama Y; Russell EJ; Stern J; Muraro P; Rose J; Testori A; Bucha J; Jovanovic B; Milanetti F; Storek J; Voltarelli JC; Burns WH
    Lancet Neurol; 2009 Mar; 8(3):244-53. PubMed ID: 19186105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices.
    Wilson L; Loucks A; Bui C; Gipson G; Zhong L; Schwartzburg A; Crabtree E; Goodin D; Waubant E; McCulloch C
    J Neurol Sci; 2014 Sep; 344(1-2):80-7. PubMed ID: 25037284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life and disease-modifying treatment behaviour in relapsing-remitting multiple sclerosis--a multicentre cohort study.
    Grytten N; Aarseth JH; Espeset K; Berg Johnsen G; Wehus R; Lund C; Riise T; Haugstad R
    Acta Neurol Scand Suppl; 2012; (195):51-7. PubMed ID: 23278657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physician and patient treatment decision-making in relapsing-remitting multiple sclerosis in Europe and the USA.
    Brown H; Gabriele S; White J
    Neurodegener Dis Manag; 2018 Dec; 8(6):371-376. PubMed ID: 30451064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients.
    Giordano A; Uccelli MM; Pucci E; Martinelli V; Borreani C; Lugaresi A; Trojano M; Granella F; Confalonieri P; Radice D; Solari A;
    Mult Scler; 2010 Jan; 16(1):100-11. PubMed ID: 19995834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracorporeal photochemotherapy: a safety and tolerability pilot study with preliminary efficacy results in refractory relapsing-remitting multiple sclerosis.
    Cavaletti G; Perseghin P; Dassi M; Cavarretta R; Frigo M; Caputo D; Stanzani L; Tagliabue E; Zoia C; Grimaldi M; Isella V; Rota S; Ferrarese C; Frattola L
    Neurol Sci; 2006 Apr; 27(1):24-32. PubMed ID: 16688596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intensive social cognitive treatment (can do treatment) with participation of support partners in persons with relapsing remitting multiple sclerosis: observation of improved self-efficacy, quality of life, anxiety and depression 1 year later.
    Jongen PJ; Heerings M; Ruimschotel R; Hussaarts A; Duyverman L; van der Zande A; Valkenburg-Vissers J; van Droffelaar M; Lemmens W; Donders R; Visser LH
    BMC Res Notes; 2016 Jul; 9():375. PubMed ID: 27473375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of quality of life in patients with relapsing-remitting multiple sclerosis: a 2-year longitudinal study.
    Baumstarck K; Pelletier J; Boucekine M; Auquier P;
    Rev Neurol (Paris); 2015 Feb; 171(2):173-80. PubMed ID: 25558798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decisional role preferences, risk knowledge and information interests in patients with multiple sclerosis.
    Heesen C; Kasper J; Segal J; Köpke S; Mühlhauser I
    Mult Scler; 2004 Dec; 10(6):643-50. PubMed ID: 15584489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.